Next Article in Journal
Recent Advances in Glioma Therapy: Combining Vascular Normalization and Immune Checkpoint Blockade
Next Article in Special Issue
Biomarkers and Lung Cancer Early Detection: State of the Art
Previous Article in Journal
From Micro to Long: Non-Coding RNAs in Tamoxifen Resistance of Breast Cancer Cells
Previous Article in Special Issue
Prostate Cancer Liquid Biopsy Biomarkers’ Clinical Utility in Diagnosis and Prognosis
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Cancers
Volume 13
Issue 15
10.3390/cancers13153687
cancers-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Correction to Cancers 2021, 13(7), 1612.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Correction

Correction: Earl et al. Somatic Mutation Profiling in the Liquid Biopsy and Clinical Analysis of Hereditary and Familial Pancreatic Cancer Cases Reveals KRAS Negativity and a Longer Overall Survival. Cancers 2021, 13, 1612

by
Julie Earl
1,2,*,
Emma Barreto
1,†,
María E. Castillo
1,†,
Raquel Fuentes
1,
Mercedes Rodríguez-Garrote
1,
Reyes Ferreiro
1,
Pablo Reguera
1,
Gloria Muñoz
3,
David Garcia-Seisdedos
3,
Jorge Villalón López
1,
Bruno Sainz, Jr.
4,5,6,
Nuria Malats
2,7 and
Alfredo Carrato
1,2,8
1
Molecular Epidemiology and Predictive Tumor Markers Group, Ramón y Cajal Health Research Institute (IRYCIS), Carretera Colmenar Km 9100, 28034 Madrid, Spain
2
Biomedical Research Network in Cancer (CIBERONC), C/Monforte de Lemos 3-5. Pabellón 11, 28029 Madrid, Spain
3
Translational Genomics Core Facility, Ramón y Cajal Health Research Institute (IRYCIS), 28034 Madrid, Spain
4
Department of Biochemistry, Universidad Autónoma de Madrid (UAM), Ramón y Cajal Health Research Institute (IRYCIS), 28034 Madrid, Spain
5
Instituto de Investigaciones Biomédicas “Alberto Sols” (IIBM), CSIC-UAM, C/Arzobispo Morcillo, 4, 28029 Madrid, Spain
6
Cancer Stem Cell and Fibroinflammatory Group, Chronic Diseases and Cancer, Area 3-IRYCIS, 28029 Madrid, Spain
7
Genetic and Molecular Epidemiology Group, Spanish National Cancer Research Centre (CNIO), 28029 Madrid, Spain
8
Department of Medicine and Medical Specialties, Medicine Faculty, Alcala University, Plaza de San Diego, s/n, 28801 Alcalá de Henares, Spain
*
Author to whom correspondence should be addressed.
†
These authors contributed equally to the manuscript.
Cancers 2021, 13(15), 3687; https://doi.org/10.3390/cancers13153687
Submission received: 9 June 2021 / Accepted: 29 June 2021 / Published: 22 July 2021
(This article belongs to the Special Issue Cancer Biomarkers in Body Fluids)
Browse Figures
Versions Notes
The authors wish to make the following corrections to this paper [1]: In the published version, Figure 4 appeared as a duplication of Figure 1b. Furthermore, the legend of Figure 2 has been corrected to accurately reflect the data shown.
The correct version of Figure 2 is as follows:
Cancers 13 03687 g002 550
Figure 2. KRAS mutation status was determined in plasma from (a) sporadic PDAC cases (b) hereditary or familial PDAC (H/FPC) cases via BEAMing and mutant KRAS was more frequently detected in sporadic cases compared to H/FPC cases. BEAMing was performed using cfDNA isolated from 1 mL of plasma from 54 PDAC cases (31 familial cases and 23 sporadic cases). The frequency of mutant KRAS was 70% in sporadic cases and 16% in familial cases, which was statistically significant (p ≤ 0.001).
Figure 2. KRAS mutation status was determined in plasma from (a) sporadic PDAC cases (b) hereditary or familial PDAC (H/FPC) cases via BEAMing and mutant KRAS was more frequently detected in sporadic cases compared to H/FPC cases. BEAMing was performed using cfDNA isolated from 1 mL of plasma from 54 PDAC cases (31 familial cases and 23 sporadic cases). The frequency of mutant KRAS was 70% in sporadic cases and 16% in familial cases, which was statistically significant (p ≤ 0.001).
Cancers 13 03687 g002
The correct version of Figure 4 is as follows:
Cancers 13 03687 g004 550
Figure 4. Hereditary or familial PDAC cases have a longer overall survival (OS) compared to sporadic cases.
Figure 4. Hereditary or familial PDAC cases have a longer overall survival (OS) compared to sporadic cases.
Cancers 13 03687 g004
We stress that these errors were purely due to human error and oversight; the corrections made do not affect or change the written portion of the figure legend, the interpretation of the results, or the final conclusions of this manuscript. The manuscript will be updated. The authors would like to apologize for any inconvenience caused. All changes have been reviewed and verified by the Academic Editors.

Author Contributions

Conceptualization, J.E. and A.C.; Data curation, J.E., E.B., M.E.C., R.F. (Raquel Fuentes), M.R.-G., R.F. (Reyes Ferreiro), P.R., G.M., D.G.-S., J.V.L., B.S.J., N.M. and A.C.; Funding acquisition, A.C.; Methodology, J.E., E.B., M.E.C., G.M. and D.G.-S.; Writing—original draft, J.E., E.B., M.E.C. and A.C.; Writing—review & editing, J.E., R.F. (Raquel Fuentes), M.R.-G., R.F. (Reyes Ferreiro), P.R., G.M., D.G.-S., J.V.L., B.S.J., N.M. and A.C. All authors have read and agreed to the published version of the manuscript.

Funding

This study was funded by the Instituto de Salud Carlos III (Plan Estatal de I+D+i 2013-2016): ISCIII (PI09/02221, PI12/01635, PI15/02101 and PI18/0135) and co-financed by the European Development Regional Fund ‘‘A way to achieve Europe’’ (ERDF), the Biomedical Research Network in Cancer: CIBERONC (CB16/12/00446), Red Temática de investigación cooperativa en cáncer: RTICC (RD12/0036/0073), La Asociación Española contra el Cáncer: AECC (Grupos Coordinados Estables 2016), Fundación Mutua Madrileña (FMM)/XVI Convocatoria de Ayudas a la Investigación en Salud and Asociación Cáncer de Páncreas (ACanPan); Asociación Española de Pancreatología (AESPANC)/IV Becas de Investigación Carmen Delgado/Miguel Pérez-Mateo.

Conflicts of Interest

The authors declare no conflict of interest.

Reference

  1. Earl, J.; Barreto, E.; Castillo, M.E.; Fuentes, R.; Rodríguez-Garrote, M.; Ferreiro, R.; Reguera, P.; Muñoz, G.; Garcia-Seisdedos, D.; López, J.V.; et al. Somatic Mutation Profiling in the Liquid Biopsy and Clinical Analysis of Hereditary and Familial Pancreatic Cancer Cases Reveals KRAS Negativity and a Longer Overall Survival. Cancers 2021, 13, 1612. [Google Scholar] [CrossRef]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Earl, J.; Barreto, E.; Castillo, M.E.; Fuentes, R.; Rodríguez-Garrote, M.; Ferreiro, R.; Reguera, P.; Muñoz, G.; Garcia-Seisdedos, D.; López, J.V.; et al. Correction: Earl et al. Somatic Mutation Profiling in the Liquid Biopsy and Clinical Analysis of Hereditary and Familial Pancreatic Cancer Cases Reveals KRAS Negativity and a Longer Overall Survival. Cancers 2021, 13, 1612. Cancers 2021, 13, 3687. https://doi.org/10.3390/cancers13153687

AMA Style

Earl J, Barreto E, Castillo ME, Fuentes R, Rodríguez-Garrote M, Ferreiro R, Reguera P, Muñoz G, Garcia-Seisdedos D, López JV, et al. Correction: Earl et al. Somatic Mutation Profiling in the Liquid Biopsy and Clinical Analysis of Hereditary and Familial Pancreatic Cancer Cases Reveals KRAS Negativity and a Longer Overall Survival. Cancers 2021, 13, 1612. Cancers. 2021; 13(15):3687. https://doi.org/10.3390/cancers13153687

Chicago/Turabian Style

Earl, Julie, Emma Barreto, María E. Castillo, Raquel Fuentes, Mercedes Rodríguez-Garrote, Reyes Ferreiro, Pablo Reguera, Gloria Muñoz, David Garcia-Seisdedos, Jorge Villalón López, and et al. 2021. "Correction: Earl et al. Somatic Mutation Profiling in the Liquid Biopsy and Clinical Analysis of Hereditary and Familial Pancreatic Cancer Cases Reveals KRAS Negativity and a Longer Overall Survival. Cancers 2021, 13, 1612" Cancers 13, no. 15: 3687. https://doi.org/10.3390/cancers13153687

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop